Fulgent Genetics, Inc., founded in 2011, is a biotechnology company with a core mission to provide comprehensive genetic testing solutions through innovative technology. The company's vision is to leverage advanced genetic diagnostics to improve patient care and outcomes. Fulgent Genetics offers a range of genetic testing services, including oncology, reproductive health, and rare disease diagnostics, utilizing a proprietary technology platform that integrates data comparison algorithms, adaptive learning software, and advanced laboratory processes. Their market focus is on providing clinicians with precise and actionable diagnostic information.
Notable affiliated individuals include Ming Hsieh, a co-founder known for his contributions to the tech and biotech industries. Key investors have supported the company's growth and technological advancements. Fulgent Genetics has achieved significant milestones, such as expanding its testing capabilities and securing partnerships with healthcare providers. The company's impact is marked by its contribution to personalized medicine, aiding in early diagnosis and tailored treatment plans for various genetic conditions.
